Loading
A phase 1/2 trial of FCN-159 in childhood cancers, run by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., active and no longer recruiting.
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 is a phase 1/2 interventional study registered as NCT04954001 by Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., with 160 participants enrolled, started 2021-03-26 and due to reach its primary completion in 2025-02-28. Interventions recorded: FCN-159.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Shanghai Fosun Pharmaceutical Industrial Development and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Shares Childhood cancers (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/